Figure 4.
Combined PS-341 and 153-Sm-EDTMP therapy delays myeloma progression and bone destruction in C57BL / KaLwRij mice. (A) Schematic representation of the in vivo protocol. (B) Effect of therapy on serum IgG2b levels in 5TGM1 myeloma-bearing mice. IgG2b levels were measured by ELISA as described in “Materials and methods.” Data are means ± SD of 6 mice. (C) Percentage of change in total body weight in treatment groups receiving 153-Sm-EDTMP without or with PS-341. Tumor-bearing or normal mice were measured weekly and are presented as percentage of initial body weight ± SD. (D) Total BMD in femurs of normal mice or mice injected with 5TGM1 were measured by DEXA on days 7 and 20, n = 6 per group. (E) On day 17, one mouse per treatment group was killed, and bone marrow was used to enumerate the posttreatment clonogenicity of bone marrow–resident 5TGM1 cells. Each point represents the mean colony number per 10 fields ± SD.

Combined PS-341 and 153-Sm-EDTMP therapy delays myeloma progression and bone destruction in C57BL / KaLwRij mice. (A) Schematic representation of the in vivo protocol. (B) Effect of therapy on serum IgG2b levels in 5TGM1 myeloma-bearing mice. IgG2b levels were measured by ELISA as described in “Materials and methods.” Data are means ± SD of 6 mice. (C) Percentage of change in total body weight in treatment groups receiving 153-Sm-EDTMP without or with PS-341. Tumor-bearing or normal mice were measured weekly and are presented as percentage of initial body weight ± SD. (D) Total BMD in femurs of normal mice or mice injected with 5TGM1 were measured by DEXA on days 7 and 20, n = 6 per group. (E) On day 17, one mouse per treatment group was killed, and bone marrow was used to enumerate the posttreatment clonogenicity of bone marrow–resident 5TGM1 cells. Each point represents the mean colony number per 10 fields ± SD.

Close Modal
This Feature Is Available To Subscribers Only

or Create an Account

Close Modal
Close Modal